Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Combines Its Life Sciences and Diagnostics Businesses

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.

Agilent Technologies Inc. announces it has combined its Life Sciences Group with its Diagnostics and Genomics business, naming Lars Holmkvist the new group's president and senior vice president of Agilent, effective immediately. Holmkvist was previously president of the Diagnostics and Genomics Group and senior vice president of Agilent.

The split will see one company focused on life sciences, diagnostics and applied markets, retaining the Agilent name, and the other focused on electronic measurement, which will be named later.

Agilent, the life sciences, diagnostics and applied markets company, will be comprised of two businesses - the Chemical Analysis Group, led by Mike McMullen, current group president and Agilent senior vice president, and the new Life Sciences and Diagnostics Group, under Holmkvist as its president. Nick Roelofs, who has been president of the Life Sciences Group, will leave Agilent to pursue other business opportunities.

"We are creating a new Agilent with a simplified structure that can move quickly to develop and deliver industry-leading total workflow solutions for our customers," said William (Bill) Sullivan, Agilent president and CEO. "Lars is the ideal leader for the new group with his years of experience, depth of market knowledge and superb leadership style."

Agilent also announced that with the spinoff of its electronic measurement business, it has created a new Agilent Order Fulfillment organization. Henrik Ancher-Jensen has been named president of Agilent Order Fulfillment and senior vice president of Agilent. He replaces Gooi Soon Chai, who is joining the electronic measurement spinoff company. Ancher-Jensen was previously vice president, Global Product Supply, for Agilent's Diagnostics and Genomics Group, and corporate vice president, Global Operations, for Dako.

"Henrik understands the priority of customer satisfaction while at the same time contributing to margin expansion goals. His experience and drive for excellence makes him a great match for this important position," Sullivan said.

"The new simplified organization positions an already strong set of businesses for greater growth and shareholder return," Sullivan said.

Lars Holmkvist
Holmkvist joined Agilent in June 2012, when Agilent acquired Dako. He had been president and CEO of Dako since 2009. Before joining Dako, Holmkvist served as president, Europe, for Applied Biosystems, where he was later promoted to president, International, with responsibilities for all commercial operations outside the U.S.

Holmkvist brings more than 25 years' experience within the medical device and pharmaceutical industries, where he has held increasingly significant roles in marketing, sales and business management. He holds a degree in economics from Handelshogskolan Sundsvall in Sweden.

Henrik Ancher-Jensen
Ancher-Jensen came to Agilent in June 2012 with the acquisition of Dako. He joined Dako in 2006 as vice president, Supply Chain, and chief information officer, and was subsequently promoted to corporate vice president, Global Operations. Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE. Ancher-Jensen holds a degree in economics from Aarhus University in Denmark.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies, University of Toronto to Collaborate on Metabolomics MRM Library-Software Solution
Scientists will be provided with a robust LC/MS solution to accelerate cell biology, disease research.
Tuesday, September 30, 2014
Agilent and Daegu Gyeongbuk Institute of Science and Technology Collaborate
Neurometabolomics Center will use Agilent's bio-analytical instruments in research of biomarkers for early detection and diagnosis of brain diseases.
Friday, November 01, 2013
Agilent Reports Third-Quarter Results
Revenues were $1.65 billion for the third fiscal quarter ended July 31, 2013, down 4 percent over one year ago.
Thursday, August 15, 2013
Agilent Technologies Reports Fourth-Quarter 2012 Results
Revenues for the fourth fiscal quarter ended October 31, 2012 were $1.77 billion, up 2 percent one year ago.
Tuesday, November 20, 2012
Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
New Drug Delivery Method for Pancreatic Cancer
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!